# Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT04644250** · PHASE2 · UNKNOWN · sponsor: **Wei Ren** · enrollment: 32 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Paclitaxel liposome/Carboplatin
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT04644250
- **Lead sponsor:** Wei Ren
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644250, "Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04644250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*